Therapeutic block of estrogen action is typically achieved with conventional antagonists (CAs), compounds that displace estradiol from the estrogen receptor (ER) and induce formation of an ER conformation that cannot bind to coactivator proteins, such as the steroid receptor coactivators (SRCs). As an alternative mode for blocking estrogen action, the authors seek small molecules that act as coactivator binding inhibitors (CBIs)-that is, they compete directly with SRC3 for interaction with estradiol-bound ER. CBIs would be interesting mechanistic probes of estrogen action and might also provide an alternative, more durable endocrine therapy for hormone-responsive breast cancer, where cellular adaptations lead to resistance to CAs. The authors have designed and optimized a set of time-resolved fluorescence resonance energy transfer (TR-FRET) assays to monitor the interaction of ER with SRC3 and ligands, and they have used them in high-throughput screens to discover small-molecule CBIs that are able to disrupt this interaction. These assays also distinguish CBIs from CAs. These robust and sensitive "mix-and-measure" assays use low concentrations of ER labeled with a europium chelate as FRET donor and a Cy5-labeled SRC as acceptor. This multiplexed protocol produces excellent signal-to-noise ratios (>100) and Z′ val-
INTRODUCTION

B
LOCKING HORMONE ACTION THROUGH THE ESTROGEN RECEP-TORS (ERs), as is desirable in endocrine therapy for breast cancer and the stimulation of folliculogenesis, classically involves the use of estrogen antagonists. 1 Antiestrogens, such as tamoxifen, displace the endogenous estrogen agonist, estradiol, and change the conformation of ER, thereby blocking many of its gene regulatory functions. Antiestrogens, however, can have mixed agonist/antagonist activity, and their effectiveness in blocking ER activity in breast cancer can decrease with time, a phenomenon termed hormone resistance. 2 Therefore, we seek compounds that would interfere with ER signaling, not at the ER-ligand interaction but at the interaction of ER with its coactivator proteins.
The transcription-regulating function of the ERs, ERα and ERβ, relies on their interaction with coactivator proteins. The best studied coactivators are members of the p160 class of steroid receptor coactivators (SRCs) that functionally link ER with modification of chromatin structure and activation of the basal transcriptional machinery. 3 The interaction of the SRCs with ER is regulated by ligand-induced conformations of the ER ligand-binding domain (LBD): agonists position the Cterminal α-helix of the ER-LBD to create a hydrophobic groove that serves as a docking site for the SRCs, whereas antagonists position this helix so that it blocks coactivator binding (Fig.  1A , center and left). Crystal structures reveal that the coactivator interacts with the hydrophobic groove in the LBD through nuclear receptor interaction boxes (NR boxes), which are LXXLL sequence motifs that adopt a 2-turn amphipathic α-helical conformation. 4 In this conformation, the first and last leucine residues extend downward into the hydrophobic groove, whereas the second leucine is positioned on a hydrophobic shelf next to the groove.
This interaction between the SRC helix and ER groove provides an alternate site for blocking estrogen action. In fact, some peptides having the LXXLL sequence can block transcription induced by hormone agonists, 5 and small-molecule analogs of these peptides could also have this net antagonistic effect. In this report, we refer to compounds that block coactivator binding directly as coactivator binding inhibitors (CBIs; Although as yet untested, it is possible that CBIs might be effective in overcoming acquired resistance to CAs that can develop in endocrine therapies for breast cancer. This resistance is thought to involve the upregulation and modification of coactivators such that they can still bind to ER-CA complexes and thereby activate transcription. 3 Although structure-based design has produced some examples of molecules that appear to act through an ER CBI mechanism, [6] [7] [8] [9] their potency as inhibitors of ER-coactivator binding has been relatively poor, as is also the case with the only reported compounds discovered through high-throughput screening (HTS). 10 Higher affinity CBIs are needed as effective mechanistic probes and as leads for potential therapeutics that work through this novel mechanism of inhibition.
Classical glutathione S-transferase (GST) pull-down and other related assays traditionally used to study receptor-coactivator interactions are labor intensive and not adaptable to HTS. 11, 12 We 8 and others 6,13 have described fluorescence polarization (FP) assays for monitoring the interaction of a fluorophore-labeled SRC LXXLL peptide with the ER LBD, but this assay is also not optimal: it has low dynamic range and requires high ER concentrations (200 nM), the latter of which also makes accurate determination of K i s difficult. Thus, we sought alternative assays based on fluorescence resonance energy transfer (FRET) that might be more amenable to an HTS format.
Others have reported FRET-based assays to examine nuclear receptor-coactivator interactions, but certain features complicate their use in an HTS format: blocking and washing steps, expensive lanthanide-conjugated antibodies, [14] [15] [16] expensive biologic fluorophores, 15 or fluorescence emission ranges that overlap with many inherently fluorescent test compounds. 14 To overcome these problems, we have developed a time-resolved (TR) FRET assay. This assay monitors the interaction between the ER LBD labeled (via a streptavidin-biotin interaction) with a europium chelate and a Cy5-labeled sequence of the SRC3 coactivator protein (or, in 1 case, a Cy5-labeled ligand). The europium chelate functions as a long-lifetime (ca. millisecond) luminescent donor, and the organic fluorophore serves as the TR-FRET acceptor. By exciting the europium complex with pulsed light and gating the emission with a 50-μsec delay, background emission from the short-lifetime (nsec) organic fluorophore FRET acceptor can be eliminated. When properly optimized, the TR-FRET method gives low background signals and can be run in a homogeneous, mix-and-measure format with very low amounts of europium-labeled streptavidin and biotin-labeled ER LBD. The choice of the europium-Cy5 FRET pair allows the monitoring of acceptor emissions at longer wavelengths than other commonly used assay fluorophores such as fluorescein. Autofluorescent compounds found in libraries typically emit at wavelengths shorter than 550 nm; thus, our choice of Cy5 minimizes false positives due solely to interfering emission patterns.
Here, we present details of the development, optimization, and validation of a set of three 384-well format TR-FRET assays to discover small-molecule CBIs for ER (assay A1) and to distinguish them from CAs (assays A2 and A3). These assays are simple, sensitive, and robust, and they are characterized by excellent Z′ values and signal-to-background (S/B) ratios. Thus, they are amenable to the HTS format and can be readily used for screening large chemical libraries.
MATERIALS AND METHODS
17β-Estradiol and tamoxifen were purchased from Sigma Aldrich (St. Louis, MO), and LANCE™ streptavidin-europium chelate from PerkinElmer (Waltham, MA). Cyclononane-Cy5 was synthesized in the Katzenellenbogen laboratory, as was pyrimidine CBI, as previously reported. 8 The SRC1-Box II peptide was synthesized by the University of Illinois Protein Sciences Facility of the Carver Biotechnology Center.
Protein expression, purification, and labeling of ERα α-417, ERβ β-369, and SRC3 N-terminally His-tagged constructs in pET15b plasmids for ERα-417, ERβ-369, and SRC3 were prepared as previously described. 17 The LBDs of ERα-417 (amino acids 304-554; C381,530S) and ERβ (amino acids 256-505; C334,481S), each with a single reactive cysteine at C417 or C369, respectively, or the nuclear receptor domain of SRC3 encompassing 3 NR boxes (amino acids 627-829) were transformed into Escherichia coli BL21(DE3)pLysS, grown at 37 °C to OD 600~0 .5, induced with 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG), and grown for 4 h at 28 °C, as previously reported. 18 For protein isolation, a cell pellet was suspended in 5 mL buffer (50 mM Tris buffer [pH 7.5], 10% glycerol, 0.1 mM tris(2-carboxyethylphosphine) [TCEP]) per gram and sonicated (Vibra cell sonicator with a micro probe; Sonic Materials, Inc., Danbury, CT) for 10 s at 60% power. After centrifugation for 30 min at 30,000 g, the supernatant was purified to near homogeneity by batchwise adsorption onto a nickel-charged nitrilotriacetic acid-agarose resin (Ni-NTA-agarose; Qiagen, Inc., Santa Clarita, CA), following standard protocols. 17, 18 Site-specific ER labeling was accomplished using 30 equivalents of a thiol-reactive biotin derivative (MAL-dPEG4-biotin, Quanta BioDesign, Powell, OH), whereas His 6 -tagged ERα-417 or ERβ-369 LBDs were immobilized on the Ni-NTA resin. The SRC3-NRD was likewise labeled using the recommended equivalents of a thiol-reactive Cy5 derivative (Cy™5 Maleimide Mono-Reactive Dye Pack, Amersham Biosciences, Piscataway, NJ). Labeling reactions were incubated overnight at 4 °C in Tris-glycerol buffer (50 mM Tris [pH 7.0], 10% glycerol, 0.1 mM TCEP). Excess fluorophore was removed by washing the protein-bound resin with wash buffer (50 mM Tris buffer [pH 7.5], 10% glycerol, 10 mM mercaptoethanol) before eluting the labeled receptor using a solution of 100 mM EDTA, 0.5 M NaCl, and 20 mM Tris (pH 8.0).
17,18
FRET measurements
Assay buffer (FRET buffer) contained 20 mM Tris (pH 7.5), 0.01% Nonidet P40, and 50 mM NaCl. Black 384-well microplates (Corning Costar, Cambridge, MA) were used, and FRET signals were recorded on an Analyst HT plate reader (Molecular Devices, Sunnyvale, CA). The instrument Z height was set to 2 mm, and a 400-μs integration time was used. Europium excitation was at 330/80 nm, and emission from europium donor (D) and Cy5 acceptor (A) was measured at 620/7.5 and 665/7.5 nm, respectively. All FRET signals were expressed as A 665 /D 620 × 10 4 . The FRET signal window was considered the difference between the maximal FRET value recorded for bound SRC3-Cy5/ER, run with agonist estradiol and SA-Eu, and the minimal FRET value (background), recorded in the absence of ER. Each assay was performed with both ERα-417 and ERβ-369 with very similar results; only the assay performance with ERα-417 will be discussed.
Assay development and optimization
The primary CBI FRET assay (A1) was performed in black 384-well microplates with a total volume of approximately 20 μL per well. To determine its binding affinity, we serially diluted SRC3-Cy5 into the FRET buffer and mixed with biotin-labeled ERα-417 (0.3 nM), LANCE™ streptavidin-europium chelate (SA-Eu, 0.5 nM), and estradiol (1 µM). A 20-μL volume of this mixture was dispensed into the well, incubated at room temperature (RT) for 1 h, and measured with the Analyst HT reader. The binding affinity of ERα-417 was determined by serial dilution into the FRET buffer; mixing with SRC3-Cy5 (6 nM), SA-Eu (0.5 nM), and estradiol (1 μM); and evaluating 20 μL of this mixture as described above. To investigate the performance characteristics of the assay itself, without possible interference from test compounds, we calculated the S/B and Z′ factor based on the following equations: S/B = μ b /μ f , where μ b and μ f are the FRET signals for bound (b) ERα-417/SRC3-Cy5 and free (f) SRC3-Cy5 alone, respectively. The difference between mean signals for bound and free was represented by (μ b -μ f ). The Z′ factor was calculated using the following equa-
Assay stability was evaluated by monitoring SRC3-Cy5 recruitment to ERα-417 after incubation times from 10 min to 24 h. The effect of dimethyl sulfoxide (DMSO) on the maximal signal was evaluated by increasing solvent percentage up to 20% and measuring after a 2-h incubation at room temperature. Microsoft Excel (Microsoft Corporation, Redmond, WA), Origin 6.1 (OriginLab Corporation, Northampton, MA), and Prism 4.0 (Graphpad Software, San Diego, CA) were used to evaluate data.
An Assay Set for ER Coactivator Binding Inhibitors
Competition FRET assays using known CBIs as positive control compounds
The assay was also evaluated using 2 positive-control CBIs, an unlabeled 15-mer SRC1-Box II peptide (NH 2 -CLTERHK-ILHRLLQE-CO 2 H) and a small-molecule CBI (pyrimidine CBI), previously reported by us. 8 These were dissolved in DMSO, serially diluted, and added to assay buffer containing 0.3 nM ERα-417, 2 nM SRC3-Cy5, 0.5 nM SA-Tb, and 1 μM estradiol in a volume of 20 μL. Vehicle (DMSO) controls were also included, and plates were incubated at RT for 10 min to overnight before measurement. The percent inhibition was calculated as
with FRET signal and background as defined above. Nonlinear regression analysis using Prism 4.0 (Graphpad software) gave IC 50 values for these positive controls.
High-throughput assay format and validation
The suitability of the CBI FRET assay for HTS was determined by performing the assay in two hundred sixty 384-well microplates, with each plate containing the appropriate controls, including 16 wells of free SRC3-Cy5 (6 nM), SA-Eu (0.5 nM), and estradiol (1 μM) and 16 wells of bound ERα-417 (0.3 nM)/ SRC3-Cy5 (6 nM), SA-Eu (0.5 nM), and estradiol (1 μM). The FRET signals were used to calculate S/B ratios and Z′ factors. Assay buffer, mixed with 0.3 nM ERα-417, 6 nM SRC3-Cy5, 1 μM estradiol, and 0.5 nM SA-Eu, were dispensed in 19-μL quantities into each well before addition of library compounds as 0.5 μL of 1-mM DMSO compound stocks, yielding a final compound concentration of 25 μM and DMSO concentration of 2.6% (v/v). After 1 h at RT, plates were measured using an Analyst HT plate reader; assay data were analyzed using CambridgeSoft, and the activity cutoff was set as a percentage inhibition greater than 50%. Subsequent to a preliminary assay of a library of known pharmacologically active compounds, the LOPAC library, the concentration of SRC3-Cy5 used in the assay was decreased from 6 nM to 2 nM without any significant changes in assay parameters.
FRET confirmatory assay format and validation
Two FRET-based confirmatory assays using most of the original components were used to probe the mechanism by which tested compounds produced a decrease in FRET signal. First, to ascertain whether competition was occurring at the receptor-coactivator binding site, the primary CBI assay was repeated with 10-fold higher concentration of SRC3-Cy5 (final concentration 20 nM; assay A3). Second, to evaluate the affinity of the tested compounds for the ligand-binding site, we used ERα-417 and SA-Eu, but a fluorophore-labeled ligand, nonane-Cy5, replaced SRC3-Cy5 (assay A2). In the second assay, the concentrations of ERα-417 and nonane-Cy5 that gave the maximal signal were determined by titrating each component in the presence of fixed concentrations of the other constituents. Thus, nonane-Cy5 ligand was titrated in the presence of 0.5 nM SA-Eu and 0.3 or 1 nM ERα-417, and ERα-417 was titrated in the presence of 5 and 100 nM cyclononane-Cy5. K d values of the ligand, as well as the Z′ values and S/B ratios for these assays, were determined.
Non-fluorescence-based (ELISA) confirmatory assay format and validation
A non-fluorescence-based confirmatory enzyme-linked immunosorbent assay (ELISA) was performed in 96-well microplates coated with Protein A/G (Pierce Biotechnology, Rockford, IL) in a total volume of 100 μL per well using the FRET buffer. Full-length human estrogen receptor α and β proteins were purchased from Invitrogen (Carlsbad, CA). 17β-Estradiol (4 μM; Sigma Aldrich) was incubated with ER (~500 ng/mL) for 30 min on ice before addition of 25 μL of diluted (80 ng) mouse antihuman estrogen receptor α (Cell Signaling, Danvers, MA) or mouse antihuman estrogen receptor β (Affinity Bioreagents, Golden, CO) monoclonal antibody to the appropriate wells on the microplates. After 30 min, 25 μL of the ER/estradiol mixture was added to the microplates containing the antibodies. After 25 μL of diluted test compounds was added and allowed to incubate for 15 min, 25 μL of 60 nM biotin-labeled SRC3 was dispensed into the wells. This complete reaction mixture was allowed to incubate for 90 min at RT. The microplates were then washed 4 times with wash buffer (1× phosphate-buffered saline [PBS], 0.05% Tween-20) before 50 μL of a streptavidin-horseradish peroxidase conjugate (Jackson Immunoresearch, West Grove, PA) diluted 1:10,000 was added and incubated for 30 min. The microplates were then washed 4 times, and 100 μL of tetramethylbenzidine was added. The reaction was stopped at 10 min by addition of 100 μL of 0.1N sulfuric acid. The microplates were read at 450 nm on an Envision™ plate reader (PerkinElmer, Waltham, MA).
RESULTS AND DISCUSSION
Development, optimization, and validation of a TR-FRET estrogen receptor/SRC3 binding assay
We replaced our original FP assay for CBIs, 8 which used wild-type ER LBD, with a FRET assay by implementing an ER LBD construct, mutated to include only one reactive cysteine that could be singly labeled with a thiol-reactive biotin reagent. 17 Labeling the protein with a SA-Eu conjugate provided the long-lifetime donor for the assay that produced high signals even at low nanomolar concentrations (Fig. 2) . We chose to use a streptavidin-europium chelate, in contrast to a more conventional antibody-conjugated europium chelate targeting an epitope tag, because the smaller molecular weight of the streptavidin-europium chelate reduces the perturbation of the system. Our interest in using these components was also based on extensive studies we have performed with site-specific ER mutants in which we have determined that neither the mutation in the ER LBD nor the labeling with biotin and SA-Eu changed the biological activity of the protein in terms of its ability to bind ligand and coactivators. 17 Measurements in previous studies have demonstrated the similarity in both ligand binding and kinetic measures between ER LBD (domain E) and full-length ER (domains A-F) to support our use of the shorter construct for these experiments. 17, 18 The results of GST pull-down assays have also shown that neither mutational changes nor labeling with a small molecule have any detrimental effect on coactivator recruitment behavior of the LBD as compared with the wildtype full-length receptor. 17 No longer being restricted by the requirement of an FP assay for significant mass differences between components, we also changed the small labeled peptide previously used to a more biologically relevant, labeled protein fragment of the SRC3 coactivator, encompassing around 200 amino acids, including 3 NR boxes.
As shown in Figure 2 , increasing concentrations of either the SRC3-Cy5 (Fig. 2A) or the europium-labeled ER component (Fig. 2B) later, the signal associated with ER-SRC binding is blocked using a positive control-unlabeled SRC1-Box II peptide (cf. Fig. 4A ). Thus, these results provide a simple, reliable, and robust assay for studying ER-SRC binding and discovering small-molecule compounds that disrupt this interaction. In both titrations, the quality of the assay dynamic range for HTS suitability was assessed by calculating S/B ratios and Z′ values over the concentration range. In the SRC3-Cy5 titration, the signal window increased until ~50 nM (Fig. 2A) ; maximal S/B ratios of 140 were obtained at concentrations less than 6.25 nM, which minimized high background measurements from excess fluorophore, whereas the Z′ value for the assay remained fairly constant at around 0.95 for concentrations up to 400 nM SRCCy5 (Fig. 2C) . In the ER titration, the signal increased until 0.6 nM (Fig. 2B) ; the maximum S/B ratio was 140 at 0.625 nM ER, with a small decrease at higher concentrations, and Z′ values were ~0.95 for the entire concentration range (Fig. 2D) . S/B ratios for these assays were higher than 27 at the lowest ER concentration tested (0.08 nM). The Z′ factor of an assay incorporates both the dynamic range and variability of an assay into a single measurement, and it is considered that Z′ should be greater than 0.5 for reliable and robust assays. 13 Both titration assays show consistent Z′ factors of 0.95 over the concentration ranges, indicating that the assay is robust.
An assay suitable for HTS should also show good stability over reasonable incubation times. When we examined SRC3-Cy5 titration assays over times from 10 min to 24 h, reproducible results with no change in signal intensity were seen up to 4 h (Fig. 3A) ; thereafter, assay signal strength eventually decreased to 50%. This stability with time eliminates concern associated with dispensing large numbers of assay plates for scheduled readings during the high-throughput screen. HTS often employs compound libraries that are dissolved in solvents such as DMSO; therefore, the assay components must tolerate the presence of these solvents. The assay showed no appreciable decrease in signal with up to 8% DMSO and very little decrease with concentrations up to 20% (Fig. 3B) . The Z′ values remained constant throughout the DMSO titration, and the S/B ratios decreased only slightly with above 8% DMSO (Fig.  3C) . Thus, the ER-SRC3 interaction assay is stable in the presence of at least 8% DMSO.
Validation of the CBI assay with known peptide antagonists and small molecule CBIs
Although the ER-SRC3 interaction assay validated well, it also needed to be evaluated in a competition mode, where peptides or small molecules must displace SRC3-Cy5, as this is the mode used for screening. Component concentrations selected (0.3 nM ERα-417 and 2 nM SRC3-Cy5) were shown by previous experiments to give good signal. The concentration of SRC3-Cy5 used is about 2 times higher than its K d and provides a near-maximal signal; using a low concentration of SRC3-Cy5 is also advantageous in that it does not preclude competition by new CBI compounds. The SA-Eu label at 0.5 nM is sufficient because a single streptavidin tetramer can bind up to 4 biotin-labeled ERs. The agonist ligand estradiol was used at 1 μM, a concentration shown previously to fully saturate 0.3 nM ER (data not shown). The presence of detergent in the assay buffer, which is required to minimize nonspecific interactions, raises the apparent K d of estradiol for the ER-LBD, so a high concentration of estradiol is required. This assay, run in a competition mode under these conditions, was designated assay A1 to distinguish it from the 2 follow-up TR-FRET assays, A2 and A3 (the conditions for all 3 assays are summarized in Fig. 6D) .
The first positive control and pure inhibitor of coactivator interaction, an unlabeled SRC1-Box II peptide containing 3 LXXLL motifs, was expected to bind to ER with an IC 50~7 20 nM, based on affinities of related peptides evaluated in fluorescence polarization assays. 8 The second positive control (pyrimidine CBI), a small-molecule CBI we previously described, 8 disrupted the ER-SRC3 interaction with an IC 50 of 29 μM in an FP assay using a labeled SRC peptide as the tracer. In titration assays, these 2 positive controls demonstrated an expected dose-dependent decrease in FRET signal as they dissociated SRC3-Cy5 from ER. Assays run with incubation periods of 10 min to 24 h showed reproducible maximal signals and IC 50 s for up to 24 h for both control compounds (Fig. 4) . The IC 50 value for the unlabeled peptide after 1 h, 0.70 μM, was close to other published values (Fig. 4A) , 7 but the pyrimidine small-molecule control showed an IC 50 somewhat lower than previously published using an FP assay (Fig. 4B) . This difference in assay response is attributed to the higher sensitivity of the FRET assay, which uses lower concentrations of ER and SRC3. These results validate the CBI assay in a competition mode and confirm the conditions necessary to run this HTS assay for smallmolecule inhibitors of the ER-SRC3 interaction.
Mechanistic confirmation of hits as CBIs using FRET-based assays
Antagonist ligand competition confirmatory assay (A2).
We have used a specific sequence of 2 related TR-FRET confirmatory assays (A2 and A3) to minimize false-positive hits and verify CBI activity (the conditions for all 3 assays are summarized in Fig. 6D) . As mentioned earlier, conventional antagonists (CAs or antiestrogens) are expected to score as active in the ER-SRC3 interaction assay by competing with estradiol for binding to the ligand-binding pocket and inducing an antagonist conformation that is unable to bind coactivator (Fig. 1A) . Because a high concentration of estradiol (1 μM) is used in the FRET CBI assay (A1), however, only very high-affinity antiestrogens should show this false-positive activity. These compounds, although interesting in their own right, do not act through a CBI mechanism and must be distinguished from truepositive CBI hits.
To establish the relative ligand-binding potential of putative CBIs, we developed a binding assay that compares the hits to a Cy5-labeled ligand with known receptor affinity for the ER.
The ligand, cyclononane-Cy5 (Fig. 5E) , which we prepared expressly for this assay, binds to the ER ligand-binding pocket with approximately 23% the affinity of estradiol, as determined in a radiometric competitive binding assay (data not shown) 18, 19 ; this corresponds to a K i of 0.9 nM (estradiol K d is 0.2 nM). Simply replacing the SRC3-Cy5 component with cyclononane-Cy5 and removing estradiol gives a FRET assay that measures direct competition of compounds for binding to the ligand-binding pocket of ER, from which their affinity as CAs can be calculated (Fig. 1B) . Knowing this value, one can calculate the concentration of compound that would be required to out-compete the concentration of estradiol used in the screening assay (1 μM), thereby giving a false-positive signal as an apparent CBI in the ER-SRC3 interaction assay through a CA mechanism.
To develop this assay, we performed titrations of cyclononaneCy5 or ER while holding the other assay components constant. From titrations of cyclononane-Cy5 ligand with 0.3 or 1 nM ER and 0.5 nM SA-Eu (Fig. 5A) , we obtained an assay signal window of approximately 6000 using 1 nM ER or approximately 4000 using 0.3 nM ER, giving respective K d s of 44.9 nM and 5.8 nM. The 10-fold difference in K d determined from these titrations, however, implied that conditions were not optimal, and ligand depletion was being observed when 1 nM ER was used. Thus, the lower concentration of ER, 0.3 nM, was used in all subsequent assays. The Z′ values for each concentration of cyclononane-Cy5 were fairly steady through the titrations, never falling below 0.6 at the lowest concentrations when 0.03 nM ER was used (Fig. 5B) . The S/B ratios showed an increase with nonane-Cy5 concentration from 0 to 30 nM, then decreased at concentrations up to 200 nM but never falling below 10 (Fig. 5B) . A titration of the ER component in the presence of 5 or 100 nM cycylononane-Cy5 gave the highest assay signal windows (~10,000), Z′ values (~0.9), and S/B ratios (~235) when 100 nM cyclononane-Cy5 was used with a concentration of ER near 0.3 nM (Fig. 5C, D) . Due to the nearly identical K d values obtained from titrations at either 5 or 100 nM cyclononane-Cy5 (0.4 or 0.3 nM, respectively), concerns regarding receptor depletion were alleviated for conditions within this range, and a concentration of tracer that gave high Z′ values and S/B ratios was chosen for further assays. Therefore, the recommended conditions for this assay were determined to be 0.3 nM ER, 50 nM nonane-Cy5, and 0.5 nM SA-Eu. The ligand competition confirmatory assay, performed using these conditions, was designated as A2, and it was very valuable in identifying compounds that proved to be false positives in the CBI assay because they had conventional antagonistic activity (see below; cf. Fig. 6 ).
SRC3 competition confirmatory assay (A3).
A simple modification of the primary TR-FRET assay was used as a second counterscreen to distinguish false-positive from true-positive CBI hits: assays of positive CBI hits were repeated using 2 different concentrations of the SRC3-Cy5 (2 nM and 20 nM). The measured IC 50 values for true CBIs increased at the higher SRC-Cy5 concentration because SRC3-Cy5 competes directly with these compounds for binding at the coactivator binding site. By contrast, the IC 50 values of false-positive CBIs that were actually functioning as conventional antagonists were unaffected by changes in the SRC-Cy5 concentration because they were competing against an unchanged concentration of the agonist ligand estradiol. The assay signal window, Z′ factor, and S/B can be extrapolated from the results presented above, when run with identical components and a 10-fold higher concentration of SRC3-Cy5. This second confirmatory assay was designated as A3.
Combined use of assays A1-A3 to identify CBIs and distinguish them from CAs. The 2 positive controls, the SRC1-Box II peptide and the pyrimidine CBI, were titrated in the original assay of CBI activity (A1) and in both confirmatory assays, the ligand-binding assay (A2) and the CBI assay with 10-fold higher coactivator (A3; Fig. 6 ). The peptide showed the following activities: an IC 50 of 0.6 μM in the primary CBI assay (A1), an IC 50 of >40 μM in the ligand-binding assay (A2), and an IC 50 of 28.7 μM in the 10-fold higher coactivator assay (A3). Thus, from the large (46-fold) increase in IC 50 values in going from the CBI assay A1 to A3, the peptide appears to have good CBI activity. Also, as explained below, its potency in the ligand-binding assay (A2) is actually very low, so a CA mechanism cannot account for its CBI activity. The pyrimidine small-molecule control showed somewhat lower potency as a CBI, displaying IC 50 s of 6.2 μM, 19.7 μM, and 69.9 μM in A1, A2, and A3, respectively. Again, the 11-fold increase in IC 50 values between the assays A1 and A3 indicates that the pyrimidine has CBI activity, and its activity in the ligand-binding assay (A2) cannot account for its CBI activity.
Although both peptide and pyrimidine show activity in the ligand-binding assay (A2; IC 50 values are >40 μM and 19.7 μM, respectively), these values actually represent very low ligand-binding affinities because in the A2 assay, compounds are competing against only 50 nM of the ER ligand cyclononaneCy5, whose affinity is only 23% that of estradiol, whereas if they were functioning as CAs in the CBI assay, they would need to compete against 1 μM estradiol. Thus, the ligand-binding assay A2 is ca. 80-fold more sensitive to CA binding than are the CBI assays (A1 and A3); this factor derives from the 20-fold ligand concentration ratio (1 μM estradiol vs. 50 nM cyclononane-Cy5) and the 4-fold ligand affinity difference (100% for estradiol vs. 23% for cyclononane-Cy5).
From the IC 50 values in the A2 assay above, the known K i of cyclononane-Cy5 (0.9 nM), and its concentration in this assay (50 nM), we can estimate the K i values for peptide and pyrimidine binding to the ligand-binding pocket as ca. 200 nM, which has 1000 times lower affinity than estradiol (K d 0.2 nM). Thus, for these compounds to work in the CBI assay by a CA mechanism, whereby they would need to compete with 1 μM estradiol, one would expect them to have IC 50 values of ca. 1000 μM. Because their IC 50 values in both CBI assays are ca. 100-fold less than this, one can presume that they are functioning as true CBIs in these assays. These results support the use of the peptide and pyrimidine CBI as control compounds in these assays and establish the expected profile for newly discovered CBIs.
Furthermore, the ability of this assay set to identify and exclude false-positive hits working through a CA mechanism was verified using a known ER ligand antagonist, tamoxifen (Fig. 6C) . As expected, this compound appeared to be a CBI in the A1 assay with an IC 50 of 24.6 μM; however, further examination of the hit profile confirmed that this compound was indeed a more potent ER ligand, having an IC 50 in the A2 assay of 1.2 μM. The affinity of tamoxifen for the ligand-binding site as determined by radiometric methods (data not shown) is 1% the affinity of estradiol. Performing the same calculations as those described above, one obtains an expected IC 50 value for tamoxifen in the A2 assay of 1.3 μM, the same as the experimental results, 1.2 μM. Significantly, both CBI assays (A1 and A3) gave very similar IC 50 values (24.6 and 33.9 μM, respectively). Because there was no significant shift in potency with increased coactivator concentration, this compound does not directly compete with coactivator for the coactivator binding groove. Thus, we find, as expected, that tamoxifen would appear in a screen as a false-positive CBI by working through a CA mechanism but would be identified as such by the combined use of the 3 TR-FRET assays, A1, A2, and A3. We implemented this approach to hit evaluation to identify false-positive CAs for the remainder of the CBI hits generated from highthroughput screens.
Non-fluorescence-based confirmatory ELISA
As a low-throughput confirmatory assay for CBI active compounds that does not rely on fluorescence, we adapted a standard ELISA to detect the interaction between ER and SRC3 (Fig. 7A) . Different sources of estrogen receptor antibodies were tested to determine which would be suitable for ELISA development. The optimized conditions for the ERα (Fig. 7B) and ERβ (Fig. 7C) ELISAs show minimal nonspecific binding with the ligand or the other assay components. When using approximately 500 ng/mL of either estrogen receptor protein, 80 ng monoclonal antibody, and 60 nM biotin-labeled SRC3 NRD, the signal-to-noise (S/N) ratios for the ERα and ERβ ELISAs were 5 and 8, respectively. Under these conditions, the SRC1-Box II peptide (Fig. 7D ) and pyrimidine CBI (Fig. 7E) positive controls were tested. The peptide was active with an IC 50 of 0.07 μM (ERα) and 0.6 μM (ERβ). Pyrimidine CBI showed inhibition with an IC 50 of 23 μM on ERα but was not active on ERβ at concentrations lower than 50 μM.
High-throughput format development and validation in HTS format
The CBI FRET assay was validated for use in an HTS format by screening a total of 86,106 compounds from the Molecular Library Screening Center Network. The well-towell and plate-to-plate variation present in the assay was determined by conducting experiments on separate days. Each plate contained 16 wells of free 2 nM SRC3-Cy5 with 0.5 nM SAEu, 2.6% DMSO, and 1 μM estradiol (i.e., lacking ERα-LBD) to give the minimal FRET signal expected and 16 wells of bound ERα-417 (0.3 nM)/SRC3-Cy5 (2 nM) with 0.5 nM SA-Eu, 1 μM estradiol, and 2.6% DMSO as vehicle to give the maximal FRET signal expected. Each well contained a total volume of 19 μL dispensed by an automated robotic system. These measurements also allowed calculation of expected fluorescence values that could be used as standards in eliminating falsepositive hits due solely to compound fluorescence interference. The donor counts measured at 615 nm for the maximum signal controls were recorded and compared with that of each tested compound. Compounds with fluorescence outputs greater than 3 standard deviations from the average fluorescence output of the controls were considered to interfere with the assay and were discarded. The average FRET signal per plate from ER-SRC-Cy5 wells was consistent across plates and from day to day (Fig. 8A) . The average FRET signal from 260 plates was 4191.9 with a standard deviation of 625.3. The S/B ratios, as determined from each plate, were consistently higher than 100, and the average S/B from 260 plates was 247.4 with a SD of 58.9 (Fig. 8B) . The Z′ factor ranged from 0.7 to 0.9, with an average Z′ of 0.87 (Fig. 8B) , demonstrating a robust and consistent assay. Compounds that inhibited the binding of ER to SRC-Cy5 by more than 50% were considered potential positives, and the representative results for 15,000 compounds are shown in Figure 8C . From a screen of 86,106 compounds, a total of 1442 compounds were identified as potential positives, which resulted in a hit rate of 1.67%. This TR-FRET assay, built to discover compounds that inhibit the binding of ER to SRC3, is well suited for HTS and has been used to screen large compound libraries. The results of these screens will be described in subsequent publications.
SUMMARY
These TR-FRET assays, all of which can be performed in a simple "mix-and-measure" format, have collectively been validated as a robust and reliable system for the discovery of small-molecule compounds that disrupt the interaction between the estrogen receptor and steroid receptor coactivators. Agonist-bound estrogen receptor (labeled site specifically on biotin with streptavidin-europium) recruits a coactivator protein (SRC3 fragment labeled with Cy5), and this interaction was monitored using TR-FRET. The disruption of this binding by both peptide controls and small-molecule compounds could be followed by a decrease in FRET signal. Confirmatory TR-FRET assays were developed and optimized to identify false-positive hits, namely, conventional ER antagonists that preclude coactivator binding by an indirect mechanism in which the agonist ligand, estradiol, is displaced from the ligand-binding pocket of ER. In addition, a confirmatory assay using a colorimetric readout was optimized and implemented to eliminate any positive hits based purely on fluorescence interference. These assays, which demonstrated high stability, solvent tolerance, and good performance with small volumes, were particularly well suited for HTS. The calculated Z′ values and S/N ratios for the assays were also well above the minimal levels needed for an HTS format. The primary assay, which was used to screen approximately 86,000 compounds for CBI activity on both ERα and ERβ, is flexible and could easily be modified to screen large chemical libraries to discover CBIs, as well as conventional antagonists, for other nuclear receptors. Full HTS and follow-up medicinal chemistry results will be described in forthcoming publications from our laboratories.
